CYTOVATION

cytovation-logo

Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

#SimilarOrganizations #People #Financial #Website #More

CYTOVATION

Social Links:

Industry:
Biotechnology Life Science Medical

Founded:
2001-01-01

Address:
Bergen, Hordaland, Norway

Country:
Norway

Website Url:
http://www.cytovation.com

Total Employee:
1+

Status:
Active

Contact:
+47 55 97 09 60

Email Addresses:
[email protected]

Total Funding:
200 M NOK

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics


Similar Organizations

refeyn-logo

Refeyn

Refeyn is specialising in label-free single molecule imaging and mass measurement.

calimmune-logo

Calimmune

Calimmune is a clinical-stage gene therapy company.

virometix-logo

Virometix

Virometix is a privately held biotechnology company developing


Current Advisors List

professor-rolf-bjerkvig_image

Professor Rolf Bjerkvig Board of Directors @ Cytovation
Board_member

ole-erik-iversen_image

Ole-Erik Iversen Board of Advisors @ Cytovation
Advisor

per-eystein-lรธnning_image

Per Eystein Lรธnning Board of Directors @ Cytovation
Board_member

Current Employees Featured

kjell-inge-arnevig_image

Kjell-Inge Arnevig
Kjell-Inge Arnevig CEO @ Cytovation
CEO
2014-09-01

lars-prestegarden_image

Lars Prestegarden
Lars Prestegarden Chief scientific officer @ Cytovation
Chief scientific officer

Founder


lars-prestegarden_image

Lars Prestegarden

Investors List

canica_image

Canica

Canica investment in Series A - Cytovation

project-sandwater_image

Project Sandwater

Project Sandwater investment in Series A - Cytovation

Official Site Inspections

http://www.cytovation.com Semrush global rank: 4.31 M Semrush visits lastest month: 2.66 K

  • Host name: webcluster41.webpod11-cph3.one.com
  • IP address: 77.111.240.168
  • Location: Denmark
  • Latitude: 55.7123
  • Longitude: 12.0564
  • Timezone: Europe/Copenhagen

Loading ...

More informations about "Cytovation"

Cytovation - Precision medicine for patients with ฮฒ โ€ฆ

Cytovationโ€™s technology is broadly applicable across solid tumor types, particularly those driven by the Wnt/ฮฒ-catenin signaling pathway. Learn more about our Pipeline. News. Stay up to date on our latest news and โ€ฆSee details»

Cytovation ASA - Leading the way in immunotherapy

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly โ€ฆSee details»

Cytovation - Crunchbase Company Profile & Funding

Cytovation AS is a privately-held biotech company, specialising . View contacts for Cytovation to access new leads and connect with decision-makers.See details»

Cytovation - LinkedIn

Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells.See details»

Cytovation ASA - Our Technology

Our approach eliminates cancer cells by forming pores in the plasma membrane, releasing cancer specific antigens to the immune system, promoting an inflammatory microenvironment and โ€ฆSee details»

Cytovation 2025 Company Profile: Valuation, Funding โ€ฆ

Cytovation General Information Description. Developer of a synthetic peptide designed to provide treatment for benign skin tumors and various types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action โ€ฆSee details»

Cytovation - Funding, Financials, Valuation & Investors - Crunchbase

Cytovation AS is a privately-held biotech company, specialising . New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. ... How much funding has this โ€ฆSee details»

Press Release Distribution and Management - GlobeNewswire

Feb 15, 2023 Brings total Series A funding to over $28 million allowing CyPep-1 to advance into Phase 2 Bergen, Norway, June 2, 2023 โ€“ Cytovation ASA, a clinical stage immune-oncology โ€ฆSee details»

Cytovation Company Profile - Craft

Cytovation is a clinical-stage immune-oncology company that provides engineering synthetic peptides. It develops CyPep-1, a tumor membrane-targeted immunotherapy for the treatment โ€ฆSee details»

Cytovation Company Information - Funding, Investors, and More

The company Cytovation has raised a total of $20.37m in funding over 1 rounds. Key Insights: Series A: $20.37m; 2022. Cytovation Series A (2022, $20M) $20.37m. Similar startup. Wattif โ€ฆSee details»

Cytovation Appoints Martin Dewhurst to its Board of Directors

Feb 13, 2025 Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 12, 2025 โ€“ Cytovation ASA, a clinical stage oncology company focused on the development of its โ€ฆSee details»

Cytovation ASA - Our Pipeline

Cytovation develops treatments for solid tumors in oncology and rare diseases. Menu Menu; A new approach. CY-101 helps the immune system to fight cancer by exposing tumor โ€ฆSee details»

Cytovation Appoints Martin Dewhurst to its Board of

Feb 13, 2025 Cytovation ASA is a clinical stage immune-oncology company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual โ€ฆSee details»

Cytovation AS kicks-off with $20m Series A financing

Jan 25, 2022 Norway's immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater. ADVERTISEMENT. The Bergen University โ€ฆSee details»

Cytovation Appoints Martin Dewhurst to its Board of Directors

Feb 13, 2025 Brings over 30 years of life sciences industry experience; Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 13, 2025 โ€“ Cytovation ASA, a clinical โ€ฆSee details»

CY-101 by Cytovation for Triple-Negative Breast Cancer (TNBC ...

Dec 30, 2024 CytovationA (Cytovation) is a biotech company that develops novel therapeutic agents for skin diseases and infections. The companyโ€™s lead candidate includes CyPep-1 is a โ€ฆSee details»

Cytovation Announces Clinical Collaboration with MSD to Evaluate โ€ฆ

Jun 30, 2021 Cytovation AS is a privately held, clinical stage immune-oncology company focused on the development of CyPep-1, a first-in-class tumorolytic agent targeting the cell โ€ฆSee details»

Cancer Research UK, Cytovation and the Norwegian Cancer โ€ฆ

Jan 23, 2025 Cytovation ASA is a clinical stage biotech company focused on the development of CY-101, a first-in-class bifunctional immunotherapy. CY-101 has a unique dual mechanism of โ€ฆSee details»

Cytovation Appoints Martin Dewhurst to its Board of Directors

Feb 13, 2025 Brings over 30 years of life sciences industry experience; Co-led the McKinsey Global Life Sciences practice; Bergen, Norway, February 12, 2025 - Cytovation ASA, a clinical โ€ฆSee details»

Cytovation to present full safety and efficacy data from the CICILIA ...

Sep 16, 2024 CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/ฮฒ-catenin signalling CY-101 granted Orphan Drug Designation in US for the โ€ฆSee details»

linkstock.net © 2022. All rights reserved